Document is current
Any future updates will be listed below
-
Authors
Hamid, O. https://orcid.org/0000-0002-8238-4655
Ekström-Rydén, V. https://orcid.org/0009-0000-6053-3392
Mehmi, I. https://orcid.org/0000-0002-2253-2206
Wang, D. https://orcid.org/0000-0002-3341-8652
Patel, M. https://orcid.org/0000-0003-4127-3147
Alsaqal, S. https://orcid.org/0000-0001-7874-8084
Irenaeus, S. https://orcid.org/0000-0002-2107-7512
Nordström, C.
Sandin, LC
Grauers Wiktorin, H. https://orcid.org/0000-0002-4412-5695
Lövgren, T. https://orcid.org/0000-0003-2170-0682
Eriksson, E.
Leja-Jarblad, J.
Loskog, A. https://orcid.org/0000-0001-8583-6138
Ullenhag, GJ https://orcid.org/0000-0003-4949-3267
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2024-03471)
Barncancerfonden (PR2021-0061)
Cancerfonden (23 2698 Pj H)
Lokon Pharma AB sponsored the clinical trial
- License Information
-
More Information
Article History
Received: 17 September 2025
Accepted: 5 February 2026
First Online: 16 February 2026
Competing interests
: Drs. Loskog, Eriksson, Sandin, Leja-Jarblad, and Ms. Norström are employees of Lokon Pharma AB. Dr. Loskog is a board member of Lokon Pharma AB and an alternate board member of Nexttobe AB. Further, she is the inventor of a patent owned by Lokon Pharma AB in regard to LOAd703 and holds a research grant together with Dr. Lövgren from Lokon Pharma AB. Other authors do not report any conflicts of interest in regard to the data presented in the paper.
